GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chongqing Genrix Biopharmaceutical Co Ltd (SHSE:688443) » Definitions » ROE %

Chongqing Genrix Biopharmaceutical Co (SHSE:688443) ROE % : -24.07% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Chongqing Genrix Biopharmaceutical Co ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Chongqing Genrix Biopharmaceutical Co's annualized net income for the quarter that ended in Mar. 2024 was ¥-655.08 Mil. Chongqing Genrix Biopharmaceutical Co's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was ¥2,721.51 Mil. Therefore, Chongqing Genrix Biopharmaceutical Co's annualized ROE % for the quarter that ended in Mar. 2024 was -24.07%.

The historical rank and industry rank for Chongqing Genrix Biopharmaceutical Co's ROE % or its related term are showing as below:

SHSE:688443' s ROE % Range Over the Past 10 Years
Min: -337.99   Med: -197.48   Max: -33.52
Current: -33.52

During the past 5 years, Chongqing Genrix Biopharmaceutical Co's highest ROE % was -33.52%. The lowest was -337.99%. And the median was -197.48%.

SHSE:688443's ROE % is ranked better than
56.64% of 1347 companies
in the Biotechnology industry
Industry Median: -43.45 vs SHSE:688443: -33.52

Chongqing Genrix Biopharmaceutical Co ROE % Historical Data

The historical data trend for Chongqing Genrix Biopharmaceutical Co's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chongqing Genrix Biopharmaceutical Co ROE % Chart

Chongqing Genrix Biopharmaceutical Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
- - - -337.99 -56.97

Chongqing Genrix Biopharmaceutical Co Quarterly Data
Dec19 Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -49.97 -23.86 -32.47 -24.07

Competitive Comparison of Chongqing Genrix Biopharmaceutical Co's ROE %

For the Biotechnology subindustry, Chongqing Genrix Biopharmaceutical Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chongqing Genrix Biopharmaceutical Co's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chongqing Genrix Biopharmaceutical Co's ROE % distribution charts can be found below:

* The bar in red indicates where Chongqing Genrix Biopharmaceutical Co's ROE % falls into.



Chongqing Genrix Biopharmaceutical Co ROE % Calculation

Chongqing Genrix Biopharmaceutical Co's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-801.319/( (29.082+2784.232)/ 2 )
=-801.319/1406.657
=-56.97 %

Chongqing Genrix Biopharmaceutical Co's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=-655.08/( (2784.232+2658.792)/ 2 )
=-655.08/2721.512
=-24.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.


Chongqing Genrix Biopharmaceutical Co  (SHSE:688443) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-655.08/2721.512
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-655.08 / 0.024)*(0.024 / 3522.9965)*(3522.9965 / 2721.512)
=Net Margin %*Asset Turnover*Equity Multiplier
=-2729500 %*0*1.2945
=ROA %*Equity Multiplier
=N/A %*1.2945
=-24.07 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-655.08/2721.512
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-655.08 / -655.08) * (-655.08 / -680.1) * (-680.1 / 0.024) * (0.024 / 3522.9965) * (3522.9965 / 2721.512)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.9632 * -2833750 % * 0 * 1.2945
=-24.07 %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Chongqing Genrix Biopharmaceutical Co ROE % Related Terms

Thank you for viewing the detailed overview of Chongqing Genrix Biopharmaceutical Co's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Business Description

Traded in Other Exchanges
N/A
Address
No. 699, Maliu Avenue, Area A, Building 2, International Bio City, Banan, Chongqing, CHN, 401338
Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.
Executives
Jiang Ren Sheng Director

Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Headlines

No Headlines